DUBLIN, February 19, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/sls9qg/companion) has announced the addition of the "Concise Analysis of the International Companion Diagnostics Market - Forecast to 2019" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Companion diagnostics facilitate the enhancement of a specific drug treatment by the patient's response at every stage of treatment. These tests specify whether the patient is likely to respond to the treatment or witness adverse reactions, and also enable optimization of dosing concentrations of the drug. The medications currently available commercially are becoming more and more personalized or targeted to specific patient populations. The development of a companion diagnostic along with the drug enables shortened drug development processes as its efficacy is already mapped by the patient outcomes. Hence, use of companion diagnostics increase the possibility of a drug attaining regulatory approval and also helps in evading long clinical trial design as only the targeted patient population needs to participate in the clinical trials.
The escalating costs involved in drug discovery and development have created a need for development of cost effective solutions. Many pharmaceutical companies are now focusing on the co-development of companion diagnostics along with the drug. This co-development strategy enables the commercialization of safer and efficient drug candidates. With the advent of personalized medicine and unfolding of human genome complexity, many pharmaceutical companies have reconsidered their current business models by moving away from ill-defined therapeutics to more specific personalized or targeted therapies.
Companion diagnostics provide insights about various issues associated with any type of drug treatment such as adverse reactions, toxicity and patient stratification. Pharmaceutical manufacturers are therefore focusing on development of tailor made therapies with the help of diagnostics manufacturers, in order to cater to the increasing demand for disease-specific therapies and defined target population. A large number of companion diagnostics are being developed in the field of oncology due to the continuous exploration of cancer-specific biomarkers, advanced technological platforms and large populations affected by different types of cancers.
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Companion Diagnostics Market, by Indication, 2011 - 2019 (USD Million)
5 Companion Diagnostics Market, by Geography, 2011 - 2019 (USD Million)
6 Competitive Landscape
8 Company Profiles
- Abbott Laboratories
- Agendia NV
- Agilent Technologies, Inc
- bioMérieux SA
- BioGenex Laboratories Inc
- GE Healthcare Ltd
- Genomic Health, Inc
- Life Technologies Corporation
- Qiagen NV
- Resonance Health Analysis Services Pty Ltd
- Roche Holdings AG
- Siemens Healthcare
For more information visit http://www.researchandmarkets.com/research/sls9qg/companion
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets